Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36% av aksjene i PCI Biotech Holding ASA.
Related Questions
What does Hawkeye Invest AS' increased stake indicate about its confidence in PCI Biotech's future performance?
Is this acquisition part of a broader strategic move by Øystein Barmen that could affect PCI Biotech's operations or partnerships?
Could the 5.36% ownership trigger further buying activity or influence corporate actions that might impact the stock's liquidity and price?